Khan AH, Reaney M, Guillemin I, Nelson L, Qin S, Kamat S, Mannent L, Amin N, Whalley D, Hopkins C. Development of Sinonasal Outcome Test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps. Laryngoscope. 2022 May;132(5):933-41. doi: 10.1002/lary.29766
Mogle J, Hill NL, Bratlee-Whitaker E, Bhargava S. Within-person associations of self-reports of memory impairment and depressive symptoms in older adults: moderation of relationships over time by personality. J Gerontol B Psychol Sci Soc Sci. 2022 Feb 3;77(2):300-11. doi: 10.1093/geronb/gbab080
Han JK, Bachert C, Lee SE, Hopkins C, Heffler E, Hellings PW, Peters AT, Kamat S, Whalley D, Qin S, Nelson L, Siddiqui S, Khan AH, Li Y, Mannent LP, Guillemin I, Chuang CC. Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2022 Feb;132(2):265-71. doi: 10.1002/lary.29888
Hill NL, Mogle J, Bhargava S, Whitaker E, Bhang I, Capuano AW, Arvanitakis Z, Bennett DA, Barnes LL. Differences in the associations between memory complaints and depressive symptoms among black and white older adults. J Gerontol B Psychol Sci Soc Sci. 2020 May 9;75(4):783-91. doi: 10.1093/geronb/gby091
Trivedi MS, Coe AM, Vanegas A, Kukafka R, Crew KD. Chemoprevention uptake among women with atypical hyperplasia and lobular and ductal carcinoma in situ. Cancer Prev Res. 2017 Aug;10(8):434-41. doi: 10.1158/1940-6207.CAPR-17-0100
Hayes AF, Montoya AK, Rockwood NJ. The analysis of mechanisms and their contingencies: PROCESS versus structural equation modeling. AMJ. 2017 Feb;25(1):76-81. doi: 10.1016/j.ausmj.2017.02.001
Codony-Servat J, Marin-Aguilera M, Visa L, Garcia-Albeniz X, Pineda E, Fernandez PL, Filella X, Gascon P, Mellado B. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. Prostate. 2013 Apr;73(5):512-21. doi: 10.1002/pros.22591
Rothman KJ. The effect of alcohol consumption on risk of cancer of the head and neck. Laryngoscope. 1978 Jan;88(Suppl(pt 2)):51-5.